Cipher Gene Tech
Cipher Gene Tech is a bio medical big data analysis and interpretation platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | CNY100m | Series C | |
| Total Funding | 000k | ||
Related Content
Established in October 2015, Cipher Gene Tech operates at the intersection of genomics and artificial intelligence, positioning itself as a precision medicine service provider. The company, with headquarters in Beijing, China, and Lewes, Delaware, in the US, focuses on developing an automated platform for the analysis and interpretation of genetic data. Its primary market consists of third-party research institutes, universities, and hospitals. Cipher Gene Tech generates revenue by providing high-quality data analysis, support services, and genetic testing products related to inherited diseases and cancer to these institutions.
The core of the company's offering is an intelligent platform designed to automate and visualize the interpretation of complex genetic data, aiming to enhance the accuracy of clinical diagnoses. This service is particularly focused on the field of childhood genetic diseases, where it assists physicians in making more efficient and precise treatment decisions. The business model hinges on collaboration; by working closely with clinical doctors and research organizations, Cipher Gene continually refines its algorithms and workflows. The company has successfully navigated multiple funding rounds, including a seed round in February 2016 and a Series C round in May 2024, accumulating total funding of over $30 million.
Cipher Gene Tech's platform is supported by a multidisciplinary team with expertise in bioinformatics, molecular biology, genetics, and statistics. This integrated team is responsible for testing, optimizing, and integrating the various algorithms and protocols necessary for analyzing different types of genetic data. The company operates within the Laboratory Services (Healthcare) industry, with a vertical focus on Artificial Intelligence & Machine Learning, Life Sciences, and Oncology. Investors include entities such as Jinjiang Development, Tsinghua Innovation Ventures, and TusStar Incubator, reflecting confidence in its specialized market approach. Keywords: genetic data analysis, precision medicine, bioinformatics platform, inherited disease testing, cancer genetic testing, clinical diagnosis support, genomics, artificial intelligence in healthcare, molecular biology, data interpretation service, laboratory services, oncology diagnostics, genetic analysis, childhood genetic diseases, clinical genomics, DNA sequencing analysis, bioinformatics services, venture capital-backed, life sciences technology, healthcare data analytics